Skip to main content
Explore URMC
menu

A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer

Research Question:
What is the effect of SM-88 therapy on pancreatic cancer?

Basic Study Information

Purpose:
A prospective, open-label phase 2 trial in metastatic pancreatic cancer subjects who have failed at least one line of any prior chemotherapy. The trial is designed to evaluate the of SM-88 therapy on pancreatic cancer and will measure multiple efficacy and safety endpoints, including overall response rate, overall survival, progression free survival, relevant biomarkers, quality of life and safety. In the initial stage of the trial (36 subjects), two dose levels of SM-88's metyrosine-derivative will be evaluated.

Location: University of Rochester Medical Center
Study Reference #: IGIP18042

Lead Researcher (Principal Investigator)

Lead Researcher: Marcus Noel

Study Contact Information

Study Coordinator: Chris LeFeber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Return to Search